Biotech · Public company · Boston, MA, US
X4 Pharmaceuticals, Inc
Ticker XFOR · SEC CIK 0001501697
Track this companyFree. Adds X4 Pharmaceuticals, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials101 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline14
- MavorixaforPhase 3 · NeutropeniaClinicalTrials.gov · fetched Nov 12, 2026
- MavorixaforPhase 3 · WHIM SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- axitinibPhase 2 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- X4P-001Phase 2 · WHIM SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- X4P-001Phase 2 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- EfavirenzPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 1 · Waldenstrom's MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- MavorixaforPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- MavorixaforPhase 1 · Waldenstrom's MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
- MavorixaforPhase 1 · Hepatic InsufficiencyClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- X4P-001Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionPHASE1 · COMPLETED · started Feb 28, 2025ClinicalTrials.gov NCT06858696 · fetched Nov 12, 2026
- Drug-Drug Interaction Potential of MavorixaforPHASE1 · COMPLETED · started Feb 18, 2025ClinicalTrials.gov NCT06914869 · fetched Nov 12, 2026
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsPHASE3 · RECRUITING · started Jun 6, 2024ClinicalTrials.gov NCT06056297 · fetched Nov 12, 2026
- A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersPHASE1_PHASE2 · COMPLETED · started Oct 16, 2021ClinicalTrials.gov NCT04154488 · fetched Nov 12, 2026
- A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4PHASE1 · COMPLETED · started Apr 30, 2020ClinicalTrials.gov NCT04274738 · fetched Nov 12, 2026
- Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromePHASE3 · COMPLETED · started Oct 24, 2019ClinicalTrials.gov NCT03995108 · fetched Nov 12, 2026
- Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaPHASE1_PHASE2 · TERMINATED · started Dec 7, 2016ClinicalTrials.gov NCT02923531 · fetched Nov 12, 2026
- A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromePHASE2 · COMPLETED · started Dec 1, 2016ClinicalTrials.gov NCT03005327 · fetched Nov 12, 2026
- X4P-001 and Pembrolizumab in Patients With Advanced MelanomaPHASE1 · COMPLETED · started Sep 15, 2016ClinicalTrials.gov NCT02823405 · fetched Nov 12, 2026
- Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaPHASE1_PHASE2 · COMPLETED · started Apr 27, 2016ClinicalTrials.gov NCT02667886 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 17, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2025 · fetched Nov 12, 2026